Vedolizumab Dosing via Predictive Biomarker Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to predict the response of patients with inflammatory bowel disease (IBD) to vedolizumab therapy and to monitor the development of autoantibodies against anti-α4β7 integrin drugs, as current treatments are not effective for all patients and can lead to adverse reactions.
Innovation Solution
The method involves detecting specific predictive markers such as TNFα, human serum albumin, VEGF, angiopoietin-1, angiopoietin-2, adenosine deaminase, serum α4β7 integrin, IL-12p40, C-reactive protein, MAdCAM-1, VCAM-1, and ICAM-1 in patient samples using assays like proximity dual detection or immunoassays to classify patients as responders or non-responders to vedolizumab and predict the likelihood of developing autoantibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If vedolizumab therapy is administered to all IBD patients, then treatment coverage is improved, but adverse reactions and autoantibody development increase
Solution Approach 1:
The patent applies preliminary action by measuring predictive markers (such as baseline serum α4β7 integrin levels, MAdCAM-1, VCAM-1, ICAM-1, and other inflammatory markers) before initiating vedolizumab therapy. This pre-screening allows identification of patients most likely to respond to treatment, enabling clinicians to prescribe vedolizumab only to appropriate candidates rather than all IBD patients, thereby improving treatment coverage for responders while minimizing adverse reactions in non-responders
Solution Approach 2:
The patent implements feedback mechanisms by monitoring changes in predictive markers during therapy. Serial measurements of serum α4β7 integrin, MAdCAM-1, VCAM-1, ICAM-1, and other markers allow assessment of treatment response over time. This feedback enables adjustment of therapy - continuing vedolizumab for patients showing positive marker changes and discontinuing or switching therapy for patients with inadequate response, thus optimizing the balance between treatment coverage and adverse reaction prevention
2Reliability
If predictive marker profiling is performed to identify responders, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic process into distinct components: (1) baseline assessment of serum α4β7 integrin levels as a primary predictor, (2) measurement of secondary markers (MAdCAM-1, VCAM-1, ICAM-1), and (3) evaluation of clinical response parameters. This segmented approach allows clinicians to start with the most predictive marker and add other measurements only when needed, improving treatment efficacy through comprehensive profiling while managing diagnostic complexity through hierarchical assessment
Solution Approach 2:
The patent applies universality by developing a multi-functional predictive marker panel that serves multiple purposes: (1) predicting initial response to vedolizumab induction therapy, (2) monitoring ongoing treatment response during maintenance therapy, and (3) identifying patients at risk of losing response or developing autoantibodies. This universal marker panel reduces the need for separate diagnostic tests for different clinical scenarios, thereby improving treatment efficacy across various stages while simplifying the overall diagnostic process
3Measurement precision
If multiple predictive markers are monitored, then prediction accuracy is improved, but measurement time and cost increase
Solution Approach 1:
The patent applies dynamics by creating a flexible, adaptive measurement strategy rather than a fixed protocol. The frequency and depth of marker monitoring are dynamically adjusted based on clinical context: (1) baseline comprehensive profiling before therapy initiation, (2) intermediate monitoring at key time points (e.g., week 6 after induction), and (3) routine monitoring intervals during maintenance therapy. This dynamic approach maintains high prediction accuracy by measuring multiple markers when most informative while reducing measurement time during stable treatment phases
Solution Approach 2:
The patent applies partial action by implementing a tiered marker assessment strategy. Not all predictive markers are measured with equal frequency or depth for every patient. Instead, the protocol measures serum α4β7 integrin and key markers (MAdCAM-1, VCAM-1, ICAM-1) at essential time points to achieve sufficient prediction accuracy, rather than performing exhaustive measurements of all possible markers at all time points. This partial measurement approach maintains clinically adequate prediction accuracy while significantly reducing measurement time and cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized treatment by identifying patients likely to respond to vedolizumab and minimizing the risk of autoantibody development, optimizing therapy and reducing adverse reactions.
Implementation Method 1
detecting the presence or level of at least one predictive marker selected from the group consisting of TNFα, human serum albumin (HSA), VEGF, angiopoietin-1 (ANG-1), angiopoietin-2 (ANG-2), adenosine deaminase (ADA), serum α4β7 integrin, IL-12p40, C-reactive protein (CRP), matrix metalloproteinase 9 (MMP9), MAdCAM-1, VCAM-1, ICAM-1, or a combination thereof in a sample from the subject
Data Source
AI summary
The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-α4β7 integrin drug.